Heidi Health, a Blackbird Ventures-backed medical artificial intelligence platform, has launched a new product suite that moves beyond clinical documentation to complete routine administrative work. The company announced Heidi II at a customer event on September 28, showing how autonomous agents can prepare charts, arrange referrals, and identify patients due for follow-up care. The launch follows a funding round that valued the Australian healthtech company at A$1.26 billion.
From Documentation to Autonomous Action
Heidi II introduces agentic capabilities that act on the tasks surrounding each patient visit rather than simply recording them. The platform currently supports 2.8 million patient visits per week and has identified more than 400 million follow-up tasks since February 2024. New agents can draft pre-visit notes, complete referral communications, and run panel sweeps for immunizations, blood tests, and screening recalls.
The new Home view gives clinicians a daily summary with patients, sessions, and tasks already loaded. Users can attach sessions, patients, and external files as context, then ask Heidi II to complete work in plain language. Routines allow an individual clinician or an entire practice to schedule recurring workflows, while connectors enable the system to operate across calendars, inboxes, portals, and electronic health records.
Funding and Competitive Dynamics
The launch follows a funding round of A$140 million led by existing investor Blackbird Ventures, bringing Heidi Health's valuation to A$1.26 billion. The company also secured US$335 million from General Catalyst's customer value fund, which pre-funds sales, marketing, and customer acquisition costs in exchange for a share of future revenue. Heidi Health now operates in 190 countries and has supported more than 175 million visits globally.
Despite rapid growth, the company faces competition from AI scribe rival Lyrebird Health and from electronic health record providers such as Epic Systems and Oracle Health. Co-founder Thomas Kelly said some United States investors were conflicted by existing positions or cautious about the level of competition, which is why Blackbird led the round. He added that large artificial intelligence financings are absorbing significant capital in a tight funding market.
Regulatory and Safety Safeguards
Heidi Health has designed its agents with clinician supervision and approval controls because clinical judgment remains with the practitioner. The company does not allow agents to prescribe, diagnose, or order medical investigations, as these activities would trigger Australia's medical device rules. Its internal clinical safety teams review features before and after release, and capabilities are staged by region and care setting.
The platform will not be available in the UK or EU because of tighter AI regulations in those markets. Digital Rights Watch has called for stronger accountability safeguards, while the Therapeutic Goods Administration has said Australia's framework is fit for purpose and flexible enough to accommodate emerging technologies. Kelly said stricter regulation could create a defensive moat, but also cautioned against stifling innovation.
Rollout and Early Use Cases
Heidi II begins rolling out on September 29 in English and French, with additional languages to follow. The initial launch will reach clinicians in Australia and other selected markets, while the United Kingdom and European Union are excluded for regulatory reasons. Early users have described meaningful time savings because preparation that previously happened between patient appointments can now be completed in advance.
Heidi Health is positioning Heidi II as an AI care partner that can reduce administrative burden and expand clinical capacity. The product's ability to act across existing systems could differentiate it from legacy practice management software, although competition and regulatory oversight remain significant factors. If the staged rollout proceeds safely, the company's latest platform may give clinicians more time for direct patient care.